% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • michaelroman910 michaelroman910 Aug 22, 2013 2:26 AM Flag

    Article : We see no pullback on INCY shares. // post

    Motley Fool 8/23/13
    As you can tell by today's move higher, this is incredibly good early stage news for advanced metastatic pancreatic sufferers. Furthermore, it appears that Incyte has already honed in on which subgroups would benefit most by JAK pathway inhibition, meaning that a companion diagnostic test may be unnecessary. Jakafi delivered improved overall survivial in a phase 3 myelofibrosis trial, which lends hope that ruxolitinib to treat metastatic prostate cancer will do the same. With regard to Incyte, I'd love to see a pullback from today's pop but would certainly understand if it didn't.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
76.98-4.68(-5.73%)Jun 24 4:00 PMEDT